1. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. (14th May 2019) Authors: Hastings, K; Yu, H A; Wei, W; Sanchez-Vega, F; DeVeaux, M; Choi, J; Rizvi, H; Lisberg, A; Truini, A; Lydon, C A; Liu, Z; Henick, B S; Wurtz, A; Cai, G; Plodkowski, A J; Long, N M; Halpenny, D F; Killam, J; Oliva, I; Schultz, N Journal: Annals of oncology Issue: Volume 30:Number 8(2019) Page Start: 1311 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1503TiPCheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC. (23rd October 2018) Authors: Gettinger, S; Beck, T; Yang, X; Telivala, B; Morgensztern, D; Velcheti, V; Ramalingam, S S; Schalper, K; Dajee, M; Ranck, A; Yang, R; Spigel, D R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. LBA5Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331. (17th December 2018) Authors: Reck, M; Vicente, D; Ciuleanu, T; Gettinger, S; Peters, S; Horn, L; Audigier-Valette, C; Pardo, N; Juan-Vidal, O; Cheng, Y; Zhang, H; Shi, M; Wolf, J; Antonia, S J; Nakagawa, K; Selvaggi, G; Baudelet, C; Chang, H; Spigel, D R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. LBA58Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial. (23rd October 2018) Authors: Popat, S; Kim, H R; Ahn, M-J; Yang, J C-H; Han, J-Y; Hochmair, M J; Lee, K H; Delmonte, A; Garcia Campelo, M R; Kim, D-W; Griesinger, F; Felip, E; Califano, R; Spira, A I; Gettinger, S; Tiseo, M; Haney, J; Kerstein, D; Camidge, D R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. (2nd February 2018) Authors: Vokes, E E; Ready, N; Felip, E; Horn, L; Burgio, M A; Antonia, S J; Arén Frontera, O; Gettinger, S; Holgado, E; Spigel, D; Waterhouse, D; Domine, M; Garassino, M; Chow, L Q M; Blumenschein, G; Barlesi, F; Coudert, B; Gainor, J; Arrieta, O; Brahmer, J Journal: Annals of oncology Issue: Volume 29:Number 4(2018) Page Start: 959 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. LBA1Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial. (24th November 2019) Authors: Camidge, R; Kim, H R; Ahn, M-J; Yang, J C-H; Han, J-Y; Hochmair, M J; Lee, K H; Delmonte, A; Garcia Campelo, M R; Kim, D-W; Griesinger, F; Felip, E; Califano, R; Spira, A; Gettinger, S; Tiseo, M; Ni, Q; Zhang, P; Popat, S Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗